Statin Use is Associated with a Significant Reduction in Cholesterol Content of Erythrocyte Membranes. A Novel Pleiotropic Effect?
- 160 Downloads
High cholesterol content of erythrocyte membranes (CEM) levels is present in patients with acute coronary syndromes (ACS). Intraplaque hemorrhage and erythrocyte lysis contribute to the deposition of cholesterol on the atherosclerotic plaque and to plaque rupture. With the present study we assessed the effect of statin therapy on CEM levels, a novel marker of coronary artery disease (CAD) instability during a 1-year follow-up in CAD patients.
212 consecutive eligible (158 men, 62 ± 10 years) patients undergoing diagnostic coronary angiography for the assessment of angina pectoris were assessed. The study population comprised of 84 chronic stable angina (CSA) patients and 128 ACS patients. All study participants were commenced on statin treatment in equipotent doses and were followed for up to 1 year (at − 1, − 3, − 6 and − 12 months).
Repeated measurements analysis of variance after appropriate adjustment showed a significant decrease (p < 0.001) in CEM content during follow up. CEM levels were decreasing at each time point (1 month : 100 ug/mg 95%CI 94.3–105.6, 3 months : 78.1 ug/mg 95%CI 73.2–83, 6 months : 67.2 ug/mg 95%CI 63.1–71.2, 1 year : 45.3 ug/mg 95%CI 42.2–48.3) compared to admission (112.1 ug/mg 95% CI 105.9–118.3) and to all previous measurements.
The present study showed, that use of statins is associated with a reduction in CEM, an emerging marker of clinical instability and plaque vulnerability in CAD patients. The pleiotropic effects of statins at the cell membrane level represent a promising novel direction for research in CAD.
Key wordsErythrocyte membranes Cholesterol content Statins Coronary artery disease
- 14.Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2003;24:28–66.CrossRefPubMedGoogle Scholar
- 19.Grundy SM, Cleeman JI, Merz NB, Brewer B Jr, Clark LT, Hunninghake DB, et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–39.CrossRefPubMedGoogle Scholar
- 20.Scanlon PJ, Faxon DP, Audet AM, Scanlon PJ, Faxon DP, Audet AM, et al. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol. 1999;33:1756–824.CrossRefPubMedGoogle Scholar
- 28.Dietzen DJ, Page KL, Tetzloff TA, Bohrer A, Turk J. Inhibition of 3-hydroxy-3methylglutaryl coenzyme A (HMG CoA) reductase blunts factor VIIa/Tissue Factor and prothrombinase acitivities via effects on membrane phosphatidylserine. Arterioscler Thromb Vasc Biol. 2007;27:690–6.CrossRefPubMedGoogle Scholar
- 30.Caliskan S, Caliskan M, Kuralay F, Onvural B. Effect of simvastatin therapy on blood and tissue ATP levels and erythrocyte membrane lipid composition. Res Exp Med. 2000;199:189–94.Google Scholar
- 45.d’Hollander F, Chavallier F. Movement of cholesterol in vitro in rat blood and quantitation of the exchange of free cholesterol between plasma and erythrocytes. J Lipid Res. 1972;13:733–44.Google Scholar